24 aprile 2017

Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1]

– CDI, a potentially fatal disease,[2] isthree times as deadly asMRSA[3],[4] and is estimated to cost the EU €3 billion per annum[5]
  

New data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of extended-pulsed […]

21 aprile 2017